

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Genesys Hurley Cancer Institute 302 Kensington Avenue Flint, MI 48503 REPORT NUMBER(S) 2012-001	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
---	---

3. DOCKET NUMBER(S) 030-36106	4. LICENSE NUMBER(S) 21-32322-01	5. DATE(S) OF INSPECTION Feb. 14, 2012
--------------------------------------	---	---

6. INSPECTION PROCEDURES USED 87131 and 87132	7. INSPECTION FOCUS AREAS 03.01-07
--	---

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02230	2. PRIORITY 2	3. LICENSEE CONTACT Ahmed Akl, M.D., RSO	4. TELEPHONE NUMBER (810) 762-8490
---------------------------------	----------------------	---	---

Main Office Inspection Next Inspection Date: Feb. 2014
 Field Office Inspection
 Temporary Job Site Inspection

PROGRAM SCOPE

This licensee is a free-standing cancer treatment center with authorization to use materials in Section 35.300 and Ir-192 in an HDR unit. The radiation oncology department was staffed with 3 AMPs, and 2 authorized physician users. The licensee administered 5-6 thyroid carcinoma treatments annually; occasionally (1 case in a year) the licensee administered a Zevalin treatment. The licensee administered approximately 25-30 patient treatments annually utilizing its HDR. These treatments included a variety of cancer cases. All HDR patient treatments were administered by the attending radiation oncologist and the authorized medical physicist. Service, maintenance, and source exchanges were performed by the HDR device manufacturer.

This inspection consisted of interviews with select licensee personnel; a review of select records; a tour of the radiation oncology department; and independent measurements. The inspector observed the licensee staff administer a patient treatment utilizing its HDR unit. The inspector reviewed the patient's written directive and the treatment plan and interviewed the attending physician and AMP. The inspection included observations of HDR QA and safety checks, security of byproduct material, use of personnel monitoring, and patient surveys.